Lake Street raised the firm’s price target on MDxHealth (MDXH) to $9 from $7 and keeps a Buy rating on the shares. Following the Q3 report, the firm is increasing its price target to reflect the improved profile of the company’s portfolio and revenue growth prospects in 2026, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- MDxHealth price target raised to $7 from $5 at TD Cowen
- MDxHealth price target raised to $7 from $6 at BTIG
- Positive Outlook for MDxHealth: Strategic Moves and Undervalued Growth Potential Reinforce Buy Rating
- Mdxhealth S.A. Reports Strong Q3 Growth and Strategic Acquisition
- Positive Outlook for MDxHealth: Strategic Acquisition and Focus on High-Return Products Drive Growth Potential